New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTLGND, TGTXLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
10:00 EDTTGTXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:03 EDTLGNDLigand sees Q4 EPS 57c-62c, consensus $67c
Subscribe for More Information
08:02 EDTLGNDLigand still sees FY14 EPS $1.50-$1.55, consensus $1.54
Subscribe for More Information
08:01 EDTLGNDLigand reports Q3 EPS 36c, consensus 31c
Subscribe for More Information
07:04 EDTTGTXTG Therapeutics initiated with a Buy at H.C. Wainwright
Subscribe for More Information
October 23, 2014
09:23 EDTLGNDLigand price target raised to $121.50 from $92 at Roth Capital
Subscribe for More Information
October 22, 2014
11:14 EDTTGTXHigh option volume stocks
Subscribe for More Information
October 17, 2014
16:22 EDTTGTXRA Capital reports 8.3% passive stake in TG Therapeutics

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use